RecruitingNot ApplicableNCT05977803

Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

60 participants

Start Date

Feb 15, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of the study is to determine whether the use of the CEST sequence would have diagnostic performance equivalent to the reference method of T2\* infusion with contrast injection in the diagnosis of radionecrosis of lung cancer brain metastases.


Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Patients \> 18 years of age
  • Histologically proven primary lung cancer
  • Histologically proven or not brain metastases
  • Irradiated metastases
  • Inclusion in a treatment protocol for brain metastases by brain metastasis in toto or stereotactic or gamma-knife radiotherapy
  • Morphological increase of one or more lesions of secondary brain metastases on a follow-up MRI
  • Patients affiliated to a social security scheme

Exclusion Criteria6

  • Opposition to the study
  • Contraindication to MRI
  • Refusal of imaging by the patient
  • Patient with state medical aid (unless exemption from affiliation)
  • Severe cognitive impairment making informed consent impossible
  • Patients under guardianship or deprived of liberty

Interventions

RADIATIONMRI with CEST sequence, IVIM and ASL sequence

Three sequences will be added as part of the protocol (for an additional duration of about 10 minutes) : * The CEST sequence * The ASL infusion sequence * The IVIM sequence


Locations(1)

Hôpital Bichat-Claude Bernard

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05977803


Related Trials